Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.59 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.59 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307825 | 0.88 | PI4KA (0.65) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL260752 | 0.84 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL260716 | 0.83 | ADORA3 (0.40) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL17213440 | 0.81 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL2291671 | 0.81 | PI4KA (0.80) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL22757346 | 0.79 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL24146799 | 0.79 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL25756700 | 0.79 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL25757130 | 0.79 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL25756766 | 0.79 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133880-B2 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133880-B2 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| US-7863253-B2 | Purine Derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-20070238694-A1 | Purine compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070238694-A1 | Purine compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238694-A1 | Purine compounds and methods of use thereof | PNP, ADORA2A, P2RY1 | PI4KA 3135/4885PI4K2B 3561/4885PI4K2A 3478/4885 |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | PNP, NUDT1, HPRT1 | PI4KA 1919/4885PI4K2B 2485/4885PI4K2A 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.